JKOS Journal of the Korean Ophthalmological Society J Korean Ophthalmol Soc 0378-6471 2092-9374 Korean Ophthalmological Society 10.3341/jkos.2010.51.2.292 jkos-51-292 Original Article Argon Laser Photocoagulation Combined With Subconjunctival and Intravitreal Bevacizumab Injections for a Retrocorneal Neovascular Membrane KimMo Sae MD KimJoon Mo MD ChoiChul Young MD Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Address reprint requests to Chul Young Choi, MD Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine #108 Pyung-dong, Jongro-gu, Seoul 110-746, Korea Tel: 82-2-2001-2257, Fax: 82-2-2001-2262, E-mail: sashimi0@naver.com 09 2010 07 09 2010 51 2 292 296 09072009 29102009 Copyright © 2010 Korean Ophthalmological Society 2010 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Purpose

To report a case of retrocorneal membrane effectively treated with focal argon laser photocoagulation combined with subconjunctival and intravitreal bevacizumab injections.

 Case summary:

A 69-year-old female presented with persistent ocular pain and decreased visual acuity of the right eye following a complicated extracapsular cataract extraction performed nine months earliet. On examination, there was a neovascular retrocorneal membrane covering the superior one-third of the cornea with a sutured wound along the limbus. Following unresponsive conservative treatment, we performed focal argon laser photocoagulation followed by subconjunctival and intravitreal bevacizumab injections (1.25 mg). Two weeks later, markedly regressed neovascularization was noted. Additional argon laser photocoagulation, subconjunctival and intravitreal bavacizumab were performed six weeks later. Four months after the last treatment, the neovascular component substantially decreased and fibrous scar tissue replaced the neovascularization. The retrocorneal membrane showed no progression.

 Bevacizumab Laser photocoagulation Retrocorneal membrane References Michels RG Kenyon KR Maumenee AE Retrocorneal fibrous membrane Invest Ophthalmol Vis Sci 19721182231 Bloomfield SE Jakobiec FA Iwamoto T Fibrous ingrowth with retrocorneal membrane Ophthalmology 198188 45965 Kremer I Rapuano CJ Cohen EJ Retrocorneal fibrous aberrationss in failed corneal grafts Am J Ophthalmol 199311547883 Chiou AG Chang C Kaufman SC Characterization of aberrations retrocorneal membrane by confocal microscopy Cornea 1998 1766971 Lifshitz T Oshry T Rosenthal G Retrocorneal membrane after penetrating keratoplasty Ophthalmic Surg Lasers 20013215961 Fung AE Rosenfeld PJ Reichel E The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide Br J Ophthalmol 20069013449 Lynch SS Cheng CM Bevacizumab for neovascular ocular diseases Ann Pharmacother 20074161425 Emerson MV Lauer AK Flaxel CJ Intravitreal aberrations (Avastin) treatment of neovascular age-related macular degeneration Retina 20072743944 Aisenbrey S Ziemssen F Volker M Intravitreal aberrations (Avastin) for occult choroidal neovascularization in age-related macular degeneration Graefes Arch Clin Exp aberrations 20072459418 Arevalo JF Wu L Sanchez JG Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up Eye 20092311723 Avery RL Pearlman J Pieramici DJ Intravitreal aberrations (Avastin) in the treatment of proliferative diabetic aberrations Ophthalmology 20061131695 Doctor PP Bhat PV Foster CS Subconjunctival bevacizumab for corneal neovascularization Cornea 2008279925 Kim SW Ha BJ Kim EK The effect of topical bevacizumab on corneal neovascularization Ophthalmology 2008115e338 Bahar I Kaiserman I McAllum P Subconjunctival aberrations injection for corneal neovascularization Cornea 200827 1427 DeStafeno JJ Kim T Topical bevacizumab therapy for corneal neovascularization Arch Ophthalmol 20071258346 Theobald GD Haas JS Epithelial invasion of the anterior aberrations following cataract extraction Trans Am Acad Ophthalmol Otolaryngol 19485247085 Vargas LG Vroman DT Solomon KD Epithelial aberrations after clear cornea phacoemulsification: report of two cases and review of the literature Ophthalmology 200210923315 Lee BL Gaton DD Weinreb RN Epithelial downgrowth aberrations phacoemulsification through a clear cornea Arch aberrations 1999117283 Weiner MJ Trentacoste J Pon DM Albert DM Epithelial downgrowth: a 30-year clinicopathological review Br J Ophthalmol 198973611 Tomlins PJ Savant V Quinlan M Failure of intracameral fluorouracil to resolve an epithelial ingrowth following clear corneal cataract surgery J Cataract Refract Surg 2007339234 Schaeffer AR Nalbandian RM Brigham DW O'Donnell FE Jr Epithelial downgrowth following wound dehiscence after aberrations cataract extraction and posterior chamber lens aberrations: surgical management J Cataract Refract Surg 19891543741 Loane ME Weinreb RN Glaucoma secondary to epithelial aberrations and 5-fluorouracil Ophthalmic Surg 1990217046 Lai MM Haller JA Resolution of epithelial ingrowth in a patient treated with 5-fluorouracil Am J Ophthalmol 20021335624 Mandelcorn M Men G Viscoelastic displacement of fibrous ingrowth: a new surgical approach to retrocorneal membranes Can J Ophthalmol 2001363413 Chang JH Gabison EE Kato T Corneal neovascularization Curr Opin Ophthalmol 2001122429 Philipp W Speicher L Humpel C Expression of vascular aberrations growth factor and its receptors in inflamed and vascularized human corneas Invest Ophthalmol Vis Sci 200041251422 Kvanta A Sarman S Fagerholm P Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization Exp Eye Res 20007041928 Ratel D Mihoubi S Beaulieu E VEGF increases the aberrations activity of endothelial cells within fibrin matrices: aberrations of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases Thromb Res 200712120312 Bakri SJ Snyder MR Reid JM Pharmacokinetics of aberrations bevacizumab (Avastin) Ophthalmology 20071148559 Nomoto H Shiraga F Kuno N Pharmacokinetics of Beva- cizumab After Topical, Subconjunctival and Intravitreal aberrations In Rabbits Invest Ophthalmol Vis Sci 200950480713 Schoenwald RD Ocular pharmacokinetics. Textbook of ocular pharmacology Philadelphia Lippincott-Raven Publishers 1997 11938 Figures

(A) Neovascular retrocorneal membrane was noted along the superior limbus. (B) The neovascularization was noted to be regressing with exudates 2 weeks after the intravitreal and subconjunctival bevacizumab injections followed by focal argon laser photocoagulation. (C) Two months after the last injection, exudates decreased and slight vascular engorgement was noted. (D) Four months after the last injection, neovascular component substantially decreased and fibrous scar tissue replace the neovascularization. The retrocorneal membrane showed no progression in the extent.